Lorlatinib given European NSCLC approval

medwireNews: The ALK inhibitor lorlatinib has received a positive opinion from the EMA for use in patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).

The recommendation for conditional marketing authorisation states that lorlatinib monotherapy may be given to patients who have progressed after first-line ALK inhibitor therapy with alectinib or ceritinib, or who have used crizotinib and at least one other ALK tyrosine kinase inhibitor.

Lorlatinib has previously been approved for these indications by the US FDA.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

See also:

• Lorlatinib shows promising activity against ALK-positive advanced NSCLC
• Lorlatinib active against ALK, ROS1-rearranaged NSCLC
• Avelumab–lorlatinib shows efficacy for heavily pretreated ALK-positive NSCLC